Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis

Annals of Internal Medicine

Volumn 131, Issue 7, 1999, Pages 492-501

  Hart, Robert G ^a   Benavente, Oscar ^a   McBride, Ruth ^b   Pearce, Lesly A ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Axio Research Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; STROKE; THROMBOEMBOLISM; TREATMENT PLANNING;

EID: 0033527355     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-131-7-199910050-00003     Document Type: Article

References (32)

1. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1:175-9.
2. Gullov AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998;158:1513-21.
3. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991; 84:527-39.
4. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-91.
5. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-8.
6. The effect of low-dose warfarin on the risk for stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med. 1990;323:1505-11.
7. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:349-55.
8. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al.Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med. 1992;327:1406-12.
9. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993;342:1255-62.
10. Morocutti C, Amabile G, Fattapposta F, Nicolosi A, Matteoli S, Trappolini M, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke. 1997;28:1015-21.
11. Pengo V, Zasso A, Barbero F, Banzato A, Nante G, Parissenti L, et al. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am J Cardiol. 1998; 82:433-7.
12. Harenberg J, Weuster B. Pfitzer M, Dempfle CE, Stehle G, Kubler W, et al. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin. Semin Thromb Hemost. 1993;19(Suppl 1):116-21.
13. Posada IS, Barriales V, for the LASAF Pilot Study Group. Alternate-day dosing of aspirin in atrial fibrillation. Am Heart J. 1999;138:137-43.
14. Diener HC, Lowenthal A. Antiplatelet therapy to prevent stroke: risk of brain hemorrhage and efficacy in atrial fibrillation. J Neurol Sci. 1997;153:112.
15. Hellemons BS, Langenberg M, Lodder J, Vermeer F, Schouten HJ, Lemmens T, et al. Primary prevention of arterial thromboembolism in patients with nonrheumatic atrial fibrillation in general practice (the PATAF study) [Abstract]. Cerebrovasc Dis. 1997;7(Suppl 4):11.
16. Benavente O, Hart R, Koudstaal P, Laupacis A, McBride R. Antiplatelet therapy for preventing stroke in patients with nonvalvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. In: Warlow C, Van Gijn J, Sandercock P, eds. Stroke Module of the Cochrane Database of Systematic Reviews. Oxford: The Cochrane Collaboration; 1999. CD-ROM available from BMJ Publishing Group (London).
17. Koudstaal P. Secondary prevention following stroke or transient ischemic attack in patients with nonrheumatic atrial fibrillation: anticoagulant versus antiplatelet therapy. In: Warlow C, Van Gijn J, Sandercock P, eds. Stroke Module of The Cochrane Database of Systemic Reviews. Available in The Cochrane Library [database on disk and CD-ROM]. The Cochrane Collaboration; issue 2. Oxford: Update Software; 1997.
18. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-57.
19. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. Arch Intern Med. 1997;157:1237-40.
20. Green CJ, Hadorn DC, Bassett K, Kazanjian A. Anticoagulation in chronic nonvalvular atrial fibrillation: a critical appraisal and meta-analysis. Can J Cardiol. 1997;13:811-5.
21. Fornaro G, Rossi P, Mantica PG, Caccia ME, Aralda D, Lavezzari M, et al. Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study. Circulation. 1993;87:162-4.
22. Benavente O, Hart R, Koudstaal P, Laupacis A, McBride R. Oral anticoagulants for preventing stroke in patients with nonvalvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. In: Warlow C, Van Gijn J, Sandercock P, eds. Stroke Module of the Cochrane Database of Systematic Reviews. Oxford: The Cochrane Collaboration; 1999. CD-ROM available from BMJ Publishing Group (London).
23. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials. Stat Med. 1989;8:141-51.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials. 1986;7:177-88.
25. Hart RG. Intensity of anticoagulation to prevent stroke in patients with atrial fibrillation [Letter]. Ann Intern Med. 1998;128:408.
26. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335:540-6.
27. Hart RG, Pearce LA, Miller VT, Anderson DC, Rothrock JF, Albers GW, et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: Frequency and effect of antithrombotic agents. Cerebrovasc Dis. 1999: [in press].
28. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group Lancet. 1998;351:1755-62.
29. Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. JAMA. 1998;279: 1273-7.
30. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 1998;114(5 Suppl):579S-89S.
31. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation. Stroke. 1999;30:1223-9.
32. Feinberg WM, Kronmal RA, Newman AB, Kraut MA, Bovill EG, Cooper L, et al. Stroke risk in an elderly population with atrial fibrillation. J Gen Intern Med. 1999;14:56-9.